SLC5A2 and angina pectoris: A formerly published meta-analysis of 35 Randomized Controlled Trials (RCTs) in a total of 34,987 patients with type 2 DM showed that treatment with SGLT-2 inhibitors versus control resulted in a significant reduction by 15% in the odds for non-fatal AMI, whereas they did not confer any significant benefit on the occurrence of unstable angina [31].